Sydney-based Pharmaxis(ASX:PXS) has announced it is progressing the development of an oral anti‐fibrotic Lysyl Oxidase (LOX) inhibitor for the treatment of myelofibrosis and pancreatic cancer. …
Latest Video
Georgia Forrest
New Stories
-
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News -
Tiny fragments of RNA, a giant opportunity for autoimmune disease treatment
February 10, 2026 - - Australian Biotech -
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech